Tiffany Pluto, DO
Family Medicine · Scottdale, PANPI 1073515441
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $792 of the $980 with a category attached, or 80.8%. Novartis accounts for 80.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $840 and has fallen 85.1% since, to $125 in 2025.
Across 4 payments — averaging $244.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$792
- Intuitive Surgical$125
- AstraZeneca$48
- Boehringer Ingelheim$15
Across 742 payments — averaging $6472.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.3M
- AbbVie$1.1M
- Eli Lilly$374K
- AstraZeneca$232K
- Ardelyx, Inc.$137K
- GSK$135K
- plus $474K from 11 others
What the payments were for
- Consulting fees$79281%
- Food & beverage$17318%
- Education$152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $792 |
| Intuitive Surgical | 1 | $125 |
| AstraZeneca | 1 | $48 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$792
- Da Vinci Surgical System$125
How this compares
$980 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 127 | $142,085 |
| EliquisApixaban | 120 | $114,330 |
| MounjaroTirzepatide | 81 | $86,355 |
| JardianceEmpagliflozin | 78 | $67,373 |
| XareltoRivaroxaban | 49 | $53,164 |
| FarxigaDapagliflozin Propanediol | 66 | $48,602 |
| TrulicityDulaglutide | 38 | $43,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $35,207 |
| RybelsusSemaglutide | 21 | $22,257 |
| InvokanaCanagliflozin | 29 | $19,081 |
| MyrbetriqMirabegron | 24 | $16,440 |
| JanuviaSitagliptin Phosphate | 17 | $16,407 |
| TradjentaLinagliptin | 26 | $15,367 |
| LinzessLinaclotide | 20 | $14,445 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $14,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $15 | $98,207133 claims |
| AstraZenecaFarxiga, Symbicort | $48 | $53,86985 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Scottdale
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.